JP Morgan Chase
SNOA icon

JP Morgan Chase’s Sonoma Pharmaceuticals SNOA Stock Holding History

JP Morgan Chase’s Portfolio SNOA Stock Details SNOA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$255 Buy
123
+2
+2% +$6 ﹤0.01% 7234
2025
Q4 		$440 Sell
121
-2
-2% -$7 ﹤0.01% 7090
2025
Q3 		$477 Buy
123
+3
+3% +$12 ﹤0.01% 7056
2025
Q2 		$344 Sell
120
-18
-13% -$54 ﹤0.01% 6737
2025
Q1 		$302 Hold
138
– – ﹤0.01% 6752
2024
Q4 		$371 Hold
138
– – ﹤0.01% 6836
2024
Q3 		$424 Buy
+138
New +$704 ﹤0.01% 6819
2024
Q1 		– Sell
-1,652
Closed -$5.96K – 7850
2023
Q4 		$5.96K Buy
+1,652
New +$10.5K ﹤0.01% 6527
2023
Q2 		– Sell
-34
Closed -$1K – 7298
2023
Q1 		$1K Buy
+34
New +$876 ﹤0.01% 6550
2017
Q3 		– Sell
-2
Closed -$2K – 5162
2017
Q2 		$2K Buy
+2
New +$2.47K ﹤0.01% 4855

Other funds holding SNOA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

JP Morgan Chase's SNOA Position: Q1 2026 in Review

JP Morgan Chase increased its Sonoma Pharmaceuticals (SNOA) stake by 1.7% in Q1 2026, buying an estimated $6 and bringing the position to 123 shares worth $255. The position accounts for ﹤0.01% of the portfolio, ranked #7234.

JP Morgan Chase first reported a position in SNOA in Q2 2017 and has held it in 10 quarters since. The position peaked at $5.96K in Q4 2023. 17 funds tracked by Wall St. Rank hold SNOA as of Q1 2026.

  • JP Morgan Chase held 123 shares of Sonoma Pharmaceuticals worth $255 as of Q1 2026.
  • JP Morgan Chase bought 2 Sonoma Pharmaceuticals shares in Q1 2026, an estimated $6.
  • Sonoma Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7234 holding.
  • JP Morgan Chase first reported a position in Sonoma Pharmaceuticals in Q2 2017 and has held it in 10 quarters since.
  • JP Morgan Chase's Sonoma Pharmaceuticals position peaked at $5.96K in Q4 2023.
  • 17 funds tracked by Wall St. Rank held Sonoma Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.